These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 4440586)

  • 21. On-off effects in Parkinson's disease: a controlled investigation of ascorbic acid therapy.
    Reilly DK; Hershey L; Rivera-Calimlim L; Shoulson I
    Adv Neurol; 1983; 37():51-60. PubMed ID: 6344591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Risks in the treatment of parkinsonism with l-dopa and a dopa decarboxylase inhibitor].
    Jörg J
    Med Welt; 1979 Nov; 30(46):1740-2. PubMed ID: 537499
    [No Abstract]   [Full Text] [Related]  

  • 23. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
    Mark MH; Sage JI
    Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease and levodopa. A five-year follow-up and review.
    Markham CH; Treciokas LJ; Diamond SG
    West J Med; 1974 Sep; 121(3):188-206. PubMed ID: 4606887
    [No Abstract]   [Full Text] [Related]  

  • 25. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 26. [Abnormal movements induced by L-dopa. New therapeutic possibilities].
    Eisenring J-J ; Constantinidis J; Dick P; Yanniotis G; Tissot R
    Schweiz Med Wochenschr; 1975 Jan; 105(4):121-4. PubMed ID: 1124379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Variations in the "on-off" effect.
    Yahr MD
    Adv Neurol; 1974; 5():397-9. PubMed ID: 4440587
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of lithium on the "on-off" phenomenon in parkinsonism.
    Coffey CE; Ross DR; Ferren EL; Bragdon AC; Hurwitz BJ; Olanow CW
    Adv Neurol; 1983; 37():61-73. PubMed ID: 6858779
    [No Abstract]   [Full Text] [Related]  

  • 29. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 30. New and emerging strategies for improving levodopa treatment.
    Tolosa ES; Valldeoriola F; Martí MJ
    Neurology; 1994 Jul; 44(7 Suppl 6):S35-44. PubMed ID: 8047259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Problems and therapy of L-DOPA-induced dyskinesias].
    Völler GW; Deze J; Gundlach U; Muschard F
    Nervenarzt; 1972 Nov; 43(11):584-6. PubMed ID: 4564994
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapeutics of disordered movement.
    Sears ES
    Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Problems in the administration of L-DOPA (author's transl)].
    Ferrari E
    Riv Patol Nerv Ment; 1974 Aug; 95(4):239-50. PubMed ID: 4283417
    [No Abstract]   [Full Text] [Related]  

  • 34. Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease.
    Brusa L; Petta F; Pisani A; Moschella V; Iani C; Stanzione P; Miano R; Finazzi-Agrò E
    Neurology; 2007 May; 68(18):1455-9. PubMed ID: 17470746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of Parkinson's disease with controlled-release Carbidopa/L-DOPA.
    Pahwa R; Koller WC
    Adv Neurol; 1996; 69():487-91. PubMed ID: 8615169
    [No Abstract]   [Full Text] [Related]  

  • 36. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 37. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of thiopropazate dihydrochloride (Dartalan) in treating persisting phenothiazine-induced choreo-athetosis and akathisia.
    Bullock RJ
    Med J Aust; 1972 Aug; 2(6):314-6. PubMed ID: 4404280
    [No Abstract]   [Full Text] [Related]  

  • 39. Movement disorders in the elderly.
    Gilmore R
    Geriatrics; 1984 Jun; 39(6):65-8, 72-6. PubMed ID: 6144615
    [No Abstract]   [Full Text] [Related]  

  • 40. Parkinson's disease. Therapeutic strategies to improve patient function and quality of life.
    Danisi F
    Geriatrics; 2002 Mar; 57(3):46-50; quiz 52. PubMed ID: 11899548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.